# Stellaromics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stellaromics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.stellaromics.com
- Total disclosed funding: $80M
- Latest round: Series B (Feb 11, 2025)
- Investors on record: 2

## About

Based in Massachusetts, US, and founded in 2022 by Ye Fu, and Christopher Kroeger, Stellaromics provides the advancement of biomedical research by spearheading the development and application of 3D in situ multi-omic analysis technology. In February 2025, Stellaromics Inc. raised USD 80 million in series B funding led by new investor Catalyst Fund, with participation from another new investor Standford University. As of November 2023, Todd Dickinson operates as a Chief Executive Officer (CEO) of the company. Stellaromics Inc. is a creator of an in situ analysis technology has developed a system aimed at examining multi-omic information optically extracted from biological tissue. The company's tools are employed by utilizing a patented technology to detect high-resolution 3D transcription patterns in native biological tissue through hydrogel tissue chemistry. This approach enables researchers to explore thick tissue samples, map gene expression patterns, and maintain the spatial integrity and anatomical structure of the cells. The company plans to use November 2023 the funding to build a new headquarters and continue to enhance its product offerings.

## Funding rounds

- Series B, Feb 11, 2025, $80M — Stanford University, Catalyst Fund

## Investors

- Stanford University — Series B
- Catalyst Fund (https://capitalatlas.ai/funds/catalyst-fund) — Series B